Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that severe obesity is positively associated with more severe lower urinary tract symptoms compared to moderate obesity in patients with prostatic enlargement.

This commentary discusses how recent shifts in prostate cancer screening and management may render 5-alpha reductase inhibitors irrelevant for chemoprevention, despite evidence of their long-term safety and effectiveness in preventing low-grade prostate cancer.

Benign Prostatic Hyperplasia may be caused by changes in how the body processes male hormones.

Dihydrotestosterone gel improved well-being and sexual function in older men without negatively affecting prostate health.

This study found that minoxidil increases cytosolic-free Ca2+ levels and induces cytotoxicity in PC3 human prostate cancer cells, with the cytotoxicity occurring in a Ca2+-independent manner.

This review discusses plant-derived phytochemicals, such as phytosterols, polyphenols, and fatty acids, as potential alternatives to 5-alpha-reductase inhibitors for prostate cancer treatment, highlighting their promising anti-cancer properties and potentially fewer side effects compared to conventional drugs.

This article reviews the mechanism, use, and alternatives for finasteride in dermatology and provides no new clinical results.

This study found that metformin is inversely associated with serum PSA levels in a dose-dependent manner, suggesting further research is needed on its potential impact on prostate cancer progression.

This study found that combining 5-alpha reductase inhibitors with alpha-blockers provided the best symptomatic relief and reduced the risk of clinical progression for BPH, while PDE5 inhibitors could offset sexual side effects.

This study observed that finasteride therapy reduced PSA levels by about 40% over a year in Chinese patients with benign prostatic hyperplasia, with varying effects based on baseline PSA levels.

Scientists made the first metal-based compounds from a nonsteroidal antiandrogen drug, which showed potential in fighting both hormone-dependent and independent prostate cancer cells.

This study found that men aged 50 and older with clinical benign prostatic hyperplasia have a significantly higher prevalence of metabolic syndrome than those without the condition in the UK primary care population.

Androgens and SARMs play a role in body mass, frailty, skin health, and hair growth, and are used in treating prostate cancer, acne, and hair loss, with potential for new uses and improved versions in the future.

This study found that platelet-rich plasma treatment significantly improved erectile function and restored neural structures in aged rats with erectile dysfunction, suggesting potential benefits for geriatric patients.

Doxazosin alone or combined with finasteride improves prostate symptoms better than finasteride alone, without extra benefits.

Finasteride may cause breast enlargement, low testosterone a risk factor.

A new compound that could treat various androgen-related conditions was created and analyzed.

A new compound was made that might help treat diseases related to male hormones.

This systematic review reported that among men taking finasteride for benign prostatic hyperplasia, total PSA levels decreased by 30% to 50%, and free PSA by up to 45%, with reductions in prostate volume and PSA density observed as well.

This review explores the potential impact of SARS-CoV-2 on benign prostatic hyperplasia and related lower urinary tract symptoms but reports no new clinical results, emphasizing the need for further studies to quantify these changes.

This review focuses on the pharmacological properties, indications, contraindications, and safety profile of bicalutamide, a non-steroidal androgen receptor antagonist, in dermatological research, particularly its off-label use for improving female pattern hair loss as measured by Sinclair grading.

PSA testing is a reliable method for detecting prostate cancer, and opioids may lower PSA levels, but triglycerides don't affect prostate cancer risk.

This study determined the crystal structure and conformation of synthesized 17x-Acetoxy-pregn-4,6-diene-3,20-dione, revealing specific molecular interactions and structural details in an orthorhombic crystal system.

This study describes the molecular conformation and intermolecular interactions in the crystalline structure of the compound C24H31BrO4.

In this animal study, finasteride exposure led to impaired spermatogenesis in rats, while the novel compound DA-9401, derived from three medicinal herbs, demonstrated potential in improving sperm parameters and reducing testicular apoptosis when used alone or with finasteride.

This study found that patients with androgenetic alopecia frequently had higher PSA levels and more significant urinary symptoms, likely due to older age, though prostate weight did not differ.

This study found that prostate size varies significantly among different ethnic groups in South-Kivu, with the Lega having larger prostate volumes compared to other groups.

Patients follow treatment well, but many change medicines; good information helps compliance.

This study observed that circulating testosterone affects baseline sex differences in voiding function in C57BL/6J mice, with prostate lobe mass having a lesser impact.

This paper discusses the role of steroid sulfatase in hormone-dependent tumors and highlights the development of potent inhibitors, noting the commencement of a phase I trial for one inhibitor in postmenopausal breast cancer patients.